- published: 08 Dec 2016
- views: 1235
Create your page here
-
remove the playlistNovartis
- remove the playlistNovartis
back to playlist
We are passionate about what we do and the impact we have on patients and society. Reimagine what you could do at Novartis.
© 2016 Novartis AG
"2.500 προσλήψεις τον Ιανουάριο, ώστε να μειωθούν οι χρόνοι αναμονής των ασθενών"
- published: 05 Jan 2017
- views: 471
Novartis CEO Joe Jimenez announced fourth quarter and full year 2016 results on January 25. In his remarks Jimenez said: “Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround. Cosentyx reached blockbuster status in 2016, and the conditions are now in place for Entresto sales to accelerate in 2017. We made major strides in advancing our pipeline, executing our bolt-on M&A; strategy and implementing our new focused organization. Today we are proposing an increase in our dividend and initiating a share buyback of up to USD 5 billion. Additionally, we are reviewing options for the Alcon Division to maximize shareholder value.”
---------------
The entire Novartis AG Annual Press Conference feat. the Q&A; session is available to download via our media platform GOMEX Newsroom at http://gomex-newsroom.com/press-kit/annual-press-conference-2017-of-novartis-ag_1001.html - free download for editorial use only.
---------------
Visit the GOMEX Newsroom: http://gomex-newsroom.com
Follow us on Twitter: https://twitter.com/cmsgomex
Follow us on Google+: https://plus.google.com/+Gomex-newsroom
- published: 26 Jan 2017
- views: 15
Our mission is to discover new ways to improve and extend people's lives.
We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company.
© 2016 Novartis
- published: 30 May 2016
- views: 11140
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013.
- published: 26 Sep 2013
- views: 20173
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth.
The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur.
Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets:
iPhone: http://tinyurl.com/lvu3wyx
iPad: http://tinyurl.com/ls4tee8
Android: http://tinyurl.com/m78hwyv
For More Latest Videos, please check out
Breaking News: http://goo.gl/rXYPWO
Full Movies: http://goo.gl/mDS9IQ
Film Trailers & Events: http://goo.gl/vQ6oKl
Comedy Scenes: http://goo.gl/bpCWe2
Action Scenes: http://goo.gl/Dk3JPF
- published: 23 Dec 2015
- views: 654
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump presidency could have on the pharmaceutical industry.
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Follow WSJ on Facebook: http://www.facebook.com/wsjvideo
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJvideo
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
- published: 18 Jan 2017
- views: 369
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier.
For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml
(c) Novartis 2014
- published: 20 Nov 2014
- views: 19944
Novartis
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number one in sales (57.9 billion US$) among the world-wide industry in 2013. In July 2015, Novartis had a market-cap of around $280 billion making it the largest healthcare company by this metric.
Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include cyclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others.
In 1996, Ciba-Geigy merged with Sandoz, and the pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. Other Ciba-Geigy and Sandoz businesses were sold, or like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business.
This page contains text from Wikipedia, the Free Encyclopedia -
https://wn.com/Novartis
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
3:23Reimagine what you could do at Novartis
Reimagine what you could do at NovartisReimagine what you could do at Novartis
We are passionate about what we do and the impact we have on patients and society. Reimagine what you could do at Novartis. © 2016 Novartis AG -
37:18Ο υπ. Υγείας Αν. Ξανθός για τις προμήθειες, φακελάκια και υπόθεση Novartis
Ο υπ. Υγείας Αν. Ξανθός για τις προμήθειες, φακελάκια και υπόθεση NovartisΟ υπ. Υγείας Αν. Ξανθός για τις προμήθειες, φακελάκια και υπόθεση Novartis
"2.500 προσλήψεις τον Ιανουάριο, ώστε να μειωθούν οι χρόνοι αναμονής των ασθενών" -
20:52Σκάνδαλο Novartis:Κόστισε όσο το 1/3 του δημόσιου χρέους!!!
Σκάνδαλο Novartis:Κόστισε όσο το 1/3 του δημόσιου χρέους!!!Σκάνδαλο Novartis:Κόστισε όσο το 1/3 του δημόσιου χρέους!!!
-
45:02Novartis AG - Annual Press Conference 2017
Novartis AG - Annual Press Conference 2017Novartis AG - Annual Press Conference 2017
Novartis CEO Joe Jimenez announced fourth quarter and full year 2016 results on January 25. In his remarks Jimenez said: “Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround. Cosentyx reached blockbuster status in 2016, and the conditions are now in place for Entresto sales to accelerate in 2017. We made major strides in advancing our pipeline, executing our bolt-on M&A; strategy and implementing our new focused organization. Today we are proposing an increase in our dividend and initiating a share buyback of up to USD 5 billion. Additionally, we are reviewing options for the Alcon Division to maximize shareholder value.” --------------- The entire Novartis AG Annual Press Conference feat. the Q&A; session is available to download via our media platform GOMEX Newsroom at http://gomex-newsroom.com/press-kit/annual-press-conference-2017-of-novartis-ag_1001.html - free download for editorial use only. --------------- Visit the GOMEX Newsroom: http://gomex-newsroom.com Follow us on Twitter: https://twitter.com/cmsgomex Follow us on Google+: https://plus.google.com/+Gomex-newsroom -
1:16Novartis mission
Novartis missionNovartis mission
Our mission is to discover new ways to improve and extend people's lives. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company. © 2016 Novartis -
57:40Joe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, CEO of Novartis at Berkeley-HaasJoe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013. -
11:41Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge CityInauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth. The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur. Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets: iPhone: http://tinyurl.com/lvu3wyx iPad: http://tinyurl.com/ls4tee8 Android: http://tinyurl.com/m78hwyv For More Latest Videos, please check out Breaking News: http://goo.gl/rXYPWO Full Movies: http://goo.gl/mDS9IQ Film Trailers & Events: http://goo.gl/vQ6oKl Comedy Scenes: http://goo.gl/bpCWe2 Action Scenes: http://goo.gl/Dk3JPF -
2:56Novartis CEO Discusses Impact of Trump on Drug Industry
Novartis CEO Discusses Impact of Trump on Drug IndustryNovartis CEO Discusses Impact of Trump on Drug Industry
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump presidency could have on the pharmaceutical industry. Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy More from the Wall Street Journal: Visit WSJ.com: http://www.wsj.com Follow WSJ on Facebook: http://www.facebook.com/wsjvideo Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJvideo Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/ -
3:33Diversity & Inclusion at Novartis
Diversity & Inclusion at NovartisDiversity & Inclusion at Novartis
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier. For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml (c) Novartis 2014 -
4:24Novartis, Hyderabad (Winners)@ CDS Limelite 2016 !
Novartis, Hyderabad (Winners)@ CDS Limelite 2016 !Novartis, Hyderabad (Winners)@ CDS Limelite 2016 !
-
Reimagine what you could do at Novartis
We are passionate about what we do and the impact we have on patients and society. Reimagine what you could do at Novartis. © 2016 Novartis AG
published: 08 Dec 2016 -
Ο υπ. Υγείας Αν. Ξανθός για τις προμήθειες, φακελάκια και υπόθεση Novartis
"2.500 προσλήψεις τον Ιανουάριο, ώστε να μειωθούν οι χρόνοι αναμονής των ασθενών"
published: 05 Jan 2017 -
Σκάνδαλο Novartis:Κόστισε όσο το 1/3 του δημόσιου χρέους!!!
published: 29 Dec 2016 -
Novartis AG - Annual Press Conference 2017
Novartis CEO Joe Jimenez announced fourth quarter and full year 2016 results on January 25. In his remarks Jimenez said: “Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround. Cosentyx reached blockbuster status in 2016, and the conditions are now in place for Entresto sales to accelerate in 2017. We made major strides in advancing our pipeline, executing our bolt-on M&A; strategy and implementing our new focused organization. Today we are proposing an increase in our dividend and initiating a share buyback of up to USD 5 billion. Additionally, we are reviewing options for the Alcon Division to maximize shareholder value.” --------------- The entire Novartis AG Annual Press Conference fea...
published: 26 Jan 2017 -
Novartis mission
Our mission is to discover new ways to improve and extend people's lives. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company. © 2016 Novartis
published: 30 May 2016 -
Joe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013.
published: 26 Sep 2013 -
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth. The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur. Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets: iPhone: http://tinyurl.com/lvu3wyx iPad: http://tinyurl.com/ls4tee8 Android: http://tinyurl.com/m78hwyv For More Latest Videos, please check out Breaking News: http://goo.gl/rXYPWO Full Movies: http://goo.gl/mDS9IQ Film Trailers & Events: http://goo.gl/vQ6oKl Comedy Scenes: http://goo.gl/bpCWe2 Action Scenes: http://goo.gl/Dk3JPF
published: 23 Dec 2015 -
Novartis CEO Discusses Impact of Trump on Drug Industry
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump presidency could have on the pharmaceutical industry. Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy More from the Wall Street Journal: Visit WSJ.com: http://www.wsj.com Follow WSJ on Facebook: http://www.facebook.com/wsjvideo Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJvideo Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
published: 18 Jan 2017 -
Diversity & Inclusion at Novartis
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier. For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml (c) Novartis 2014
published: 20 Nov 2014 -
Novartis, Hyderabad (Winners)@ CDS Limelite 2016 !
published: 12 Nov 2016
Reimagine what you could do at Novartis
- Order: Reorder
- Duration: 3:23
- Updated: 08 Dec 2016
- views: 1235
We are passionate about what we do and the impact we have on patients and society. Reimagine what you could do at Novartis.
© 2016 Novartis AG
We are passionate about what we do and the impact we have on patients and society. Reimagine what you could do at Novartis.
© 2016 Novartis AG
https://wn.com/Reimagine_What_You_Could_Do_At_Novartis
We are passionate about what we do and the impact we have on patients and society. Reimagine what you could do at Novartis.
© 2016 Novartis AG
- published: 08 Dec 2016
- views: 1235
Ο υπ. Υγείας Αν. Ξανθός για τις προμήθειες, φακελάκια και υπόθεση Novartis
- Order: Reorder
- Duration: 37:18
- Updated: 05 Jan 2017
- views: 471
"2.500 προσλήψεις τον Ιανουάριο, ώστε να μειωθούν οι χρόνοι αναμονής των ασθενών"
"2.500 προσλήψεις τον Ιανουάριο, ώστε να μειωθούν οι χρόνοι αναμονής των ασθενών"
https://wn.com/Ο_Υπ._Υγείας_Αν._Ξανθός_Για_Τις_Προμήθειες,_Φακελάκια_Και_Υπόθεση_Novartis
"2.500 προσλήψεις τον Ιανουάριο, ώστε να μειωθούν οι χρόνοι αναμονής των ασθενών"
- published: 05 Jan 2017
- views: 471
Σκάνδαλο Novartis:Κόστισε όσο το 1/3 του δημόσιου χρέους!!!
- Order: Reorder
- Duration: 20:52
- Updated: 29 Dec 2016
- views: 786
- published: 29 Dec 2016
- views: 786
Novartis AG - Annual Press Conference 2017
- Order: Reorder
- Duration: 45:02
- Updated: 26 Jan 2017
- views: 15
Novartis CEO Joe Jimenez announced fourth quarter and full year 2016 results on January 25. In his remarks Jimenez said: “Novartis delivered a solid performance...
Novartis CEO Joe Jimenez announced fourth quarter and full year 2016 results on January 25. In his remarks Jimenez said: “Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround. Cosentyx reached blockbuster status in 2016, and the conditions are now in place for Entresto sales to accelerate in 2017. We made major strides in advancing our pipeline, executing our bolt-on M&A; strategy and implementing our new focused organization. Today we are proposing an increase in our dividend and initiating a share buyback of up to USD 5 billion. Additionally, we are reviewing options for the Alcon Division to maximize shareholder value.”
---------------
The entire Novartis AG Annual Press Conference feat. the Q&A; session is available to download via our media platform GOMEX Newsroom at http://gomex-newsroom.com/press-kit/annual-press-conference-2017-of-novartis-ag_1001.html - free download for editorial use only.
---------------
Visit the GOMEX Newsroom: http://gomex-newsroom.com
Follow us on Twitter: https://twitter.com/cmsgomex
Follow us on Google+: https://plus.google.com/+Gomex-newsroom
https://wn.com/Novartis_Ag_Annual_Press_Conference_2017
Novartis CEO Joe Jimenez announced fourth quarter and full year 2016 results on January 25. In his remarks Jimenez said: “Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround. Cosentyx reached blockbuster status in 2016, and the conditions are now in place for Entresto sales to accelerate in 2017. We made major strides in advancing our pipeline, executing our bolt-on M&A; strategy and implementing our new focused organization. Today we are proposing an increase in our dividend and initiating a share buyback of up to USD 5 billion. Additionally, we are reviewing options for the Alcon Division to maximize shareholder value.”
---------------
The entire Novartis AG Annual Press Conference feat. the Q&A; session is available to download via our media platform GOMEX Newsroom at http://gomex-newsroom.com/press-kit/annual-press-conference-2017-of-novartis-ag_1001.html - free download for editorial use only.
---------------
Visit the GOMEX Newsroom: http://gomex-newsroom.com
Follow us on Twitter: https://twitter.com/cmsgomex
Follow us on Google+: https://plus.google.com/+Gomex-newsroom
- published: 26 Jan 2017
- views: 15
Novartis mission
- Order: Reorder
- Duration: 1:16
- Updated: 30 May 2016
- views: 11140
Our mission is to discover new ways to improve and extend people's lives.
We use science-based innovation to address some of society's most challenging healthca...
Our mission is to discover new ways to improve and extend people's lives.
We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company.
© 2016 Novartis
https://wn.com/Novartis_Mission
Our mission is to discover new ways to improve and extend people's lives.
We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company.
© 2016 Novartis
- published: 30 May 2016
- views: 11140
Joe Jimenez, CEO of Novartis at Berkeley-Haas
- Order: Reorder
- Duration: 57:40
- Updated: 26 Sep 2013
- views: 20173
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series...
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013.
https://wn.com/Joe_Jimenez,_Ceo_Of_Novartis_At_Berkeley_Haas
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013.
- published: 26 Sep 2013
- views: 20173
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
- Order: Reorder
- Duration: 11:41
- Updated: 23 Dec 2015
- views: 654
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure wi...
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth.
The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur.
Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets:
iPhone: http://tinyurl.com/lvu3wyx
iPad: http://tinyurl.com/ls4tee8
Android: http://tinyurl.com/m78hwyv
For More Latest Videos, please check out
Breaking News: http://goo.gl/rXYPWO
Full Movies: http://goo.gl/mDS9IQ
Film Trailers & Events: http://goo.gl/vQ6oKl
Comedy Scenes: http://goo.gl/bpCWe2
Action Scenes: http://goo.gl/Dk3JPF
https://wn.com/Inauguration_Of_Novartis_Knowledge_City_Novartis_Knowledge_City_||_Novartis_Knowledge_City
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth.
The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur.
Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets:
iPhone: http://tinyurl.com/lvu3wyx
iPad: http://tinyurl.com/ls4tee8
Android: http://tinyurl.com/m78hwyv
For More Latest Videos, please check out
Breaking News: http://goo.gl/rXYPWO
Full Movies: http://goo.gl/mDS9IQ
Film Trailers & Events: http://goo.gl/vQ6oKl
Comedy Scenes: http://goo.gl/bpCWe2
Action Scenes: http://goo.gl/Dk3JPF
- published: 23 Dec 2015
- views: 654
Novartis CEO Discusses Impact of Trump on Drug Industry
- Order: Reorder
- Duration: 2:56
- Updated: 18 Jan 2017
- views: 369
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump presidency could have on the pharmaceutical industry.
Subscribe to the WS...
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump presidency could have on the pharmaceutical industry.
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Follow WSJ on Facebook: http://www.facebook.com/wsjvideo
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJvideo
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
https://wn.com/Novartis_Ceo_Discusses_Impact_Of_Trump_On_Drug_Industry
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump presidency could have on the pharmaceutical industry.
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Follow WSJ on Facebook: http://www.facebook.com/wsjvideo
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJvideo
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
- published: 18 Jan 2017
- views: 369
Diversity & Inclusion at Novartis
- Order: Reorder
- Duration: 3:33
- Updated: 20 Nov 2014
- views: 19944
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see th...
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier.
For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml
(c) Novartis 2014
https://wn.com/Diversity_Inclusion_At_Novartis
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier.
For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml
(c) Novartis 2014
- published: 20 Nov 2014
- views: 19944
Novartis, Hyderabad (Winners)@ CDS Limelite 2016 !
- Order: Reorder
- Duration: 4:24
- Updated: 12 Nov 2016
- views: 5111
- published: 12 Nov 2016
- views: 5111
- Playlist
- Chat
- Playlist
- Chat
3:23
Reimagine what you could do at Novartis
We are passionate about what we do and the impact we have on patients and society. Reimagi...
published: 08 Dec 2016
Reimagine what you could do at Novartis
Reimagine what you could do at Novartis
- Report rights infringement
- published: 08 Dec 2016
- views: 1235
37:18
Ο υπ. Υγείας Αν. Ξανθός για τις προμήθειες, φακελάκια και υπόθεση Novartis
"2.500 προσλήψεις τον Ιανουάριο, ώστε να μειωθούν οι χρόνοι αναμονής των ασθενών"
published: 05 Jan 2017
Ο υπ. Υγείας Αν. Ξανθός για τις προμήθειες, φακελάκια και υπόθεση Novartis
Ο υπ. Υγείας Αν. Ξανθός για τις προμήθειες, φακελάκια και υπόθεση Novartis
- Report rights infringement
- published: 05 Jan 2017
- views: 471
20:52
Σκάνδαλο Novartis:Κόστισε όσο το 1/3 του δημόσιου χρέους!!!
published: 29 Dec 2016
Σκάνδαλο Novartis:Κόστισε όσο το 1/3 του δημόσιου χρέους!!!
Σκάνδαλο Novartis:Κόστισε όσο το 1/3 του δημόσιου χρέους!!!
- Report rights infringement
- published: 29 Dec 2016
- views: 786
45:02
Novartis AG - Annual Press Conference 2017
Novartis CEO Joe Jimenez announced fourth quarter and full year 2016 results on January 25...
published: 26 Jan 2017
Novartis AG - Annual Press Conference 2017
Novartis AG - Annual Press Conference 2017
- Report rights infringement
- published: 26 Jan 2017
- views: 15
1:16
Novartis mission
Our mission is to discover new ways to improve and extend people's lives.
We use science-b...
published: 30 May 2016
Novartis mission
Novartis mission
- Report rights infringement
- published: 30 May 2016
- views: 11140
57:40
Joe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about l...
published: 26 Sep 2013
Joe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, CEO of Novartis at Berkeley-Haas
- Report rights infringement
- published: 26 Sep 2013
- views: 20173
11:41
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex ...
published: 23 Dec 2015
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
- Report rights infringement
- published: 23 Dec 2015
- views: 654
2:56
Novartis CEO Discusses Impact of Trump on Drug Industry
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump pres...
published: 18 Jan 2017
Novartis CEO Discusses Impact of Trump on Drug Industry
Novartis CEO Discusses Impact of Trump on Drug Industry
- Report rights infringement
- published: 18 Jan 2017
- views: 369
3:33
Diversity & Inclusion at Novartis
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions an...
published: 20 Nov 2014
Diversity & Inclusion at Novartis
Diversity & Inclusion at Novartis
- Report rights infringement
- published: 20 Nov 2014
- views: 19944
4:24
Novartis, Hyderabad (Winners)@ CDS Limelite 2016 !
published: 12 Nov 2016
Novartis, Hyderabad (Winners)@ CDS Limelite 2016 !
Novartis, Hyderabad (Winners)@ CDS Limelite 2016 !
- Report rights infringement
- published: 12 Nov 2016
- views: 5111
Reimagine what you could do at Novartis...
Ο υπ. Υγείας Αν. Ξανθός για τις προμήθειες, φακελά...
Σκάνδαλο Novartis:Κόστισε όσο το 1/3 του δημόσιου ...
Novartis AG - Annual Press Conference 2017...
Novartis mission...
Joe Jimenez, CEO of Novartis at Berkeley-Haas...
Inauguration of Novartis Knowledge City - Novartis...
Novartis CEO Discusses Impact of Trump on Drug Ind...
Diversity & Inclusion at Novartis...
Novartis, Hyderabad (Winners)@ CDS Limelite 2016 !...
See more photos of Novartis
back
Ice block the size of Delaware about to break away from Antarctica as global temperatures rise, scientists warn
Edit The Independent 03 Jul 2017
Read more ....
back
2 Massive New Holes Have Exploded Open In Siberia
Edit WorldNews.com 04 Jul 2017
The second bang was so loud it was picked up by seismic stations in neighboring settlements and near a local gas field. The new hole is approximately eight meters (26 feet) in diameter and at least 20 meters (65 feet) deep.“It happened some 35 to 40 kilometers [21 to 24 miles] northwest of Seyakha. Reindeer herder Yakov Vengo has a camp there,” fellow reindeer herder Mikhail Okotetto told local news, according to the Siberian Times ... ....
back
Mysterious Sea Creatures Spreading to Alaska Baffle Scientists
Edit WorldNews.com 04 Jul 2017
Scientists are left scratching their heads over the large pink thimble-shaped sea creatures that are suddenly popping up all over the American West Coast and now in Alaska for the first time, according to The Associated Press. Scientists know that the creatures are pyrosomes, which are tropical, filter-feeding spineless sea creatures that are usually located along the equator ... National Oceanic and Atmospheric Administration....
back
North Korea claims it tested first intercontinental missile
Edit The Miami Herald 04 Jul 2017
North Korea is claiming to have test-launched its first intercontinental ballistic missile. This appears to contradict South Korean and U.S ... ....
back
20 including journalists, retired HC judge paid through hawala to fuel Kashmir unrest
Edit One India 03 Jul 2017
The security forces along with the Intelligence Bureau have prepared a list of 20 persons including journalists and a retired High Court judge who have been fueling unrest in the Valley. The list of 20 was prepared with the ... ....
Global Heart Failure Drugs Market Size, Status and Forecast 2022
Edit Community news 04 Jul 2017
This report studies the global Heart Failure Drugs market, analyzes and researches the Heart Failure Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. For more Information on this report at http.//www.qyresearchglobal.com/goods-897848.html. This report focuses on the top players in global market, like. Pfizer. Novartis. Merck. Sanofi. Johnson & Johnson. AstraZeneca ... Amgen. Bayer ... 3.2 Novartis....
Sun Pharma to outsource manufacturing of its psoriasis drug candidate to Samsung BioLogics
Edit Moneycontrol 04 Jul 2017
Sun Pharma, India's largest drug maker on Tuesday, said it has entered into a strategic agreement with Samsung BioLogics to manufacture the former's psoriasis drug Tildrakizumab ... Sun Pharma has been developing a pipeline of specialty drugs that include Tildrakizumab (Merck), Odomzo (Novartis), MM-II (Moebius), Seciera (Ocular), Elepsia/Xelpros (SPARC), BromSite/DexaSite (Insite), Absorica (Ranbaxy), and Dusa drug products ... ....
Europe Precision Medicine Market Report 2017
Edit Community news 04 Jul 2017
This report studies the Precision Medicine market status and outlook of Europe and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in Europe and major regions, and splits the Precision Medicine market by product type and applications/end industries. The major players in Europe Precision Medicine market include. Johnson & Johnson. IBM ... Roche ... Novartis ... ....
Atopic Dermatitis Treatment Market will hit at a CAGR 12.8 % during 2017-2027
Edit Community news 04 Jul 2017
The report, titled “Atopic Dermatitis Treatment Market ... Sanofi SA, Galderma SA, Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals, Astellas Pharma Inc., Anacor Pharmaceutical Inc., Regeneron Pharmaceuticals, Aqua Pharmaceuticals (An Almirall Company), Pfizer, Dow Pharm, Connetics Corporation, Fujisawa Healthcare, Encore Dermatology, LEO Pharma, Velite Pharmaceutical, Biofrontera AG....
Osteoporosis Drugs Market Global Industry Analysis, Pipeline Analysis,Trends & Forecast
Edit Community news 04 Jul 2017
Osteoporosis is a chronic and life-threatening disease, in which microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone fragility and threat of bone cracks and fractures ... Bisphosphonates is the largest and established drug class ... Hoffmann La Roche Ltd., Merck & Co, Inc., Novartis International AG, Novo Nordisk A/S, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd....
Global Antifungal Drugs Sales Industry Analysis, Size, Share, Growth, Trends, and Forecast Report 2022
Edit Community news 04 Jul 2017
Albany, New York, July 4, 2017. Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Global Antifungal Drugs Sales Market Report 2017” to its report offerings. The report split global into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Antifungal Drugs for these regions, from 2012 to 2022 (forecast). Request Free Sample Report ... United States. China ... Novartis....
Market Live: Nifty breaks 9600 amid consolidation; all sectoral indices in red
Edit Moneycontrol 04 Jul 2017
Shiva Cement surged 13 percent, taking total rally to 50 percent in five consecutive sessions. Moneycontrol News. 12.40 pm Market Check. Equity benchmarks continued to consolidate in afternoon trade, with the Nifty hovering around 9600 level as investors await June quarter earnings that will begin next week ... The product is a generic version of Patanol, which is marketed in the US by Alcon, a subsidiary of pharma major Novartis, it added....
Market Live: Sensex strengthens again, Nifty inches towards 9650; RIL, HDFC lead
Edit Moneycontrol 04 Jul 2017
Shiva Cement surged 13 percent, taking total rally to 50 percent in five consecutive sessions. Moneycontrol News. 2.40 pm Battery price hikes. Automotive battery manufacturer Exide Industries has raised prices by 2-11 percent across segments w.e.f July 1, reports CNBC-TV18 quoting sources of Cogencis ... The product is a generic version of Patanol, which is marketed in the US by Alcon, a subsidiary of pharma major Novartis, it added ... ....
Closing Bell: Sensex ends on a flat note, Nifty closes above 9600; RIL up 3%
Edit Moneycontrol 04 Jul 2017
The Sensex closed down 11.83 points at 31209.79, while the Nifty down 1.70 points at 9613.30. Moneycontrol News. 3.30 pm Market at Close. Benchmark indices ended the session on a flat note with a negative bias, but the Nifty ended above 9600-mark ... 2.59 pm Jefferies on Hindalco ... 2.40 pm Battery price hikes ... The product is a generic version of Patanol, which is marketed in the US by Alcon, a subsidiary of pharma major Novartis, it added ... ....
Global Tobacco Alternative Gums Market 2017-2021- Key vendors are GlaxoSmithKline, Johnson & Johnson, Novartis & ...
Edit Pharmiweb 03 Jul 2017
Global Tobacco Alternative Gums Market 2017-2021- Key vendors are GlaxoSmithKline, Johnson & Johnson, Novartis & Reynolds A... Research and Markets ... ....
Young scientists benefit from time in Basel
Edit Business Day 03 Jul 2017
Swiss multinational pharmaceutical company Novartis says its programmes to promote research among young scientists are starting to bear fruit. Colin Pillai, head of global scientific capabilities at Novartis, said he hoped more private companies would promote and enable high-end scientific research in SA....
Global Soft Contact Lens Market 2017-2021 - Key vendors are CooperVision, Johnson & Johnson, Novartis ...
Edit Business Wire 03 Jul 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Soft Contact Lens Market 2017-2021" report to their offering. The analysts forecast the global soft contact lens market to grow at a CAGR of 7.64% during the period 2017-2021. Global Soft Contact Lens Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts ... The report also ... ....
Supply Planner
Edit Pharmiweb 03 Jul 2017
Salary. On Application (GBP) Benefits. Location. England, United Kingdom Frimley / Camberley Company. Novartis Posted. 03 July 2017 07.45.28 Expiry. 02 August 2017 00.00.00 ... ....
- 1
- 2
- 3
- 4
- 5
- Next page »
